"Regression to the truth": lessons learned from negative IPF trials.
Idiopathic pulmonary fibrosis (IPF) is a chronic lung disease with limited treatment options. Despite the approval of pirfenidone and nintedanib that slow disease progression, IPF remains a disease with poor survival. Promising therapeutic candidates were tested as potential treatments for IPF and w...
| Publicado en: | Breathe Vol. 21; no. 2; pp. 1 - 8 |
|---|---|
| Autores principales: | , , , |
| Formato: | questions and answers tables/charts Journal Article |
| Publicado: |
European Respiratory Society
Apr2025
|
| Acceso en línea: | Ver este registro en EBSCOhost |